The Next-Generation Landscape of Cancer Immunotherapies
SPONSORED by the SELLAS Life Sciences Group and hosted by Doug Calder
Please join the PBBG and Doug Calder on Thursday, April 12 from 5:00 to 7:00 p.m. at the Chesterfield Hotel in Palm Beach for a Special Happy Hour and Panel Reception featuring:
Happy Hour will run from 5:00 to 6:00 p.m. in the Leopard Room of the Chesterfield Hotel, and the Panel Reception featuring SELLAS Life Sciences Group will follow at 6:00 p.m. at the Pavilion Room of the Chesterfield Hotel
Event Summary: A new era of cancer immunotherapy has arrived, harnessing the body’s own natural strength to fight cancer by empowering the immune system to target and destroy malignant cells. However, despite the arrival of revolutionary therapies such as checkpoint inhibitors, CAR-T therapies, targeted antibodies and other immuno-oncology breakthrough products, patient remissions are still too often temporary due to factors such as tumor escape, immune suppression and tolerance to therapy, while treatment-related toxicity remains a concern. Therefore, there is still an urgent need to optimize these technologies in order to achieve durable, long-lasting remissions – and hopefully cures.
Join the PBBG for this special event featuring distinguished guest speakers from SELLAS Life Sciences Group (Nasdaq: SLS) who will discuss a novel approach to cancer immunotherapy by advancing its lead product, galinpepimut-S (GPS), for the potential treatment of more than 20 types of cancers including blood cancers and solid tumors such as ovarian, breast, colorectal and lung cancers. SELLAS acquired the worldwide, commercial rights to GPS from the prestigious Memorial Sloan Kettering Cancer Center in New York, which is a National Cancer Institute (NCI) Comprehensive Cancer Center.
In addition to GPS, SELLAS is advancing its targeted breast cancer peptide-based immunotherapeutic, NeuVax™. In a Phase 2b clinical trial, NeuVax™ recently showed unprecedented results by providing a significant clinical activity in prolonging disease-free survival and reducing the risk of recurrences when combined with Herceptin® in treating breast cancer patients with low HER2 expression levels (triple negative breast cancer). There are currently no targeted immunotherapies approved for triple negative breast cancer.
- Angelos Stergiou, M.D., ScD h.c., President & CEO, SELLAS Life Sciences Group
Dr. Stergiou is co-founder of SELLAS and a pioneer in the development of cancer vaccines, as well as a leading expert in medical affairs, clinical R&D, pharmacovigilance, clinical operations, regulatory affairs, biostatistics, chemistry, manufacturing & controls (CMC), health economics & pricing/reimbursement.
- Nicholas Sarlis, M.D., Ph.D., FACP, Chief Medical Officer, SELLAS Life Sciences Group
Dr. Sarlis is a global expert in the field of oncology and has held senior executive roles with Sanofi Aventis and Incyte, as well as holding previous former senior faculty positions at the National Institutes of Health (NIH) and MD Anderson Cancer Center.
- Christopher D. Krause, Ph.D., Professor, IRSC; and Chief Scientific Officer, BioMune, Inc.
Dr. Krause is an expert in the fields of interferon biology and molecular and structural immunology; he also maintains faculty appointments at the Center for Molecular Biology and Biotechnology at FAU, and the Department of Biochemistry and Molecular Biology at Robert Wood Johnson Medical School.
(taken and summarized from their web site) The SELLAS Life Sciences Group (NASDAQ:SLS; company URL by clicking the logo above or here) is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. Sellas completed its merger with Galena Biopharma at the end of 4Q17. SELLAS’ lead product candidate, licensed from Memorial Sloan-Kettering Cancer Center (MSKCC), is a late-stage innovative immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. This antigen is one of the most widely expressed cancer antigens and ranked by the National Cancer Institute (NCI) as the top priority among cancer antigens for immunotherapy. Traditional approaches have not yet been proven to successfully address the WT1 protein, as WT1 is not druggable with small molecules and is not accessible to antibodies due to its intracellular localization. SELLAS has been working with MSKCC since 2014, and MSKCC is also a current shareholder of SELLAS. SELLAS plans to initiate a pivotal Phase 3 study in acute myeloid leukemia (AML) as well as malignant pleural mesothelioma (MPM), pending funding availability. SELLAS is currently conducting Phase 1 and Phase 2 studies in multiple myeloma (MM) and ovarian cancer (combination with nivolumab (Opdivo®) and will advance additional studies into the clinic. The US FDA granted Orphan Designations and Fast Track Designations for SELLAS' WT1 therapy, galinpepimut-S, for AML and MPM and the EMA granted Orphan Designation for AML and MPM. Galinpepimut-S has the potential to complement currently available therapies by destroying residual tumor cells of cancers in remission and providing ongoing immune surveillance to avoid or significantly delay tumor recurrence. Its use in this setting is aided by a well-tolerated safety profile not yet been proven to be found in standard of care therapies. SELLAS was founded in 2012 and its headquarters are in New York City.
The Maxim Group (with a subsidiary based in West Palm Beach) recently published a research report on SELLAS. Please e-mail Christopher Krause for details, as the PBBG will not release this document publicly.